CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
LY3076226drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02529553
NCT02529553Phase 1Completed
CompareCT.gov

A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company·interventional·Posted Aug 20, 2015·Updated Apr 17, 2020

In Brief

A Phase 1 clinical trial evaluating LY3076226 for Advanced Cancer and Metastatic Cancer. Completed, enrolled 25 participants across 4 sites in 2 countries.

Detailed Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3076226 in participants with advanced or metastatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer, Metastatic Cancer
CountriesCanada, United States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 20, 2015
Enrollment StartSep 1, 2015
Primary CompletionMar 28, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.9 years ago

Interventions

LY3076226drug

Administered IV